The key is near the finish of this article; "They also want to...

The key is near the finish of this article; "They also want to see differentiated science, not just "tweaks" to things like gene and cell therapy, Davis said."
The mass of 'Me too" Car-T developers will certainly feel the pinch IMO regardless of Biden's cancer cure push.
While I have looked at some PTX alternatives on the ASX to invest in, by being Car-T only they put me off. Investing across the same field is not diversification - it is just trying to increase the chance of a win when we know that over 90% will become worthless. Unless one has a plan to exit the losers quickly and focus on the winners you are bound to be disappointed - just as buying multiple tickets in a raffle

I have seen a recent article from the US advising that there will be a few biotech companies to advance quite well from the clean-out - without any detail of who, I believe PTX has the goods to do well because it is not a tweak but a paradigm shift as long as the efficacy and price is as promoted